Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL).
Matthew S. Davids(Dana-Farber Cancer Institute), Andrew W. Roberts(The Royal Melbourne Hospital), Cathy E. Nolan(Abbott Fund), Sari H. Enschede(AbbVie (United States)), John M. Pagel(University of Washington), David E. Darden(Abbott Fund), Alison M. Graham(Abbott Fund), Rod Humerickhouse(Abbott Fund), Brenda Chyla(AbbVie (United States)), Brad S. Kahl(UW Health University Hospital), John F. Gerecitano(Memorial Sloan Kettering Cancer Center), John F. Seymour(The Royal Melbourne Hospital), William G. Wierda(University of Maryland, Baltimore), Mary Ann Anderson(The Royal Melbourne Hospital), Jianning Yang(AbbVie (United States)), Elisa Cerri(AbbVie (United States)), Todd Busman(Abbott Fund), Lori A. Gressick(AbbVie (United States))
Cited by 12
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k